

OCT 05 2007

PTO/SB/81 (01-08)

Approved for use through 12/31/2008. OMB 0651-0035  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	Application Number		10/686,809
	Filing Date		October 17, 2003
	First Named Inventor		Bernd Nickel
	Title	INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING THERAPEUTICALLY VALUABLE PROPERTIES	
	Art Unit	1614	
	Examiner Name	J. D. Anderson	
Attorney Docket No.		ZIPH-009-102	

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number: 28120

OR

☐ Practitioner(s) named below:

Name	Registration Number	Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name  
 Matthew P. Vincent, J.D., Ph.D.  
 ROPES & GRAY LLP

Address One International Place

City Boston

State MA

Zip 02110

Country US

Telephone (617) 951-7000

Email

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature		Date	10/4/07
Name	Richard Bagley	Telephone	(617) 259-1970
Title and Company President and Chief Operating Officer, Director and Treasurer of ZIOPHARM Oncology, Inc.			

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ \*Total of 1 forms are submitted.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 10/5/07

Signature:

VALERIE J. SAROSKY

OCT 05 2007

PTO/SB/96 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Nickel et al.Application No./Patent No.: 10/686,809 Filed/Issue Date: October 17, 2003Entitled: INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING THERAPEUTICALLY VALUABLE PROPERTIESZIOPHARM Oncology, Inc., a corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Nickel et al. To: ASTA Medica Aktiengesellschaft  
The document was recorded in the United States Patent and Trademark Office at  
Reel 019720, Frame 0655, or for which a copy thereof is attached.
2. From: ASTA Medica Aktiengesellschaft To: Baxter Healthcare S.A. and Baxter International Inc.  
The document was recorded in the United States Patent and Trademark Office at  
Reel 019714, Frame 0687, or for which a copy thereof is attached.
3. From: Baxter Healthcare S.A. and Baxter International Inc. To: ZIOPHARM Oncology, Inc.  
The document was recorded in the United States Patent and Trademark Office at  
Reel 019714, Frame 0701, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Richard Bagley  
Signature  
Richard Bagley  
Printed or Typed Name  
President and Chief Operating Officer, Director and Treasurer  
Title

10/4/07  
Date  
(617) 259-1970  
Telephone Number

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 10/5/07 Signature: Valerie J. Sarskey VALERIE J. SARSKEY

10734479\_1.DOC